COLO B Coloplast A/S Class B

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)

Tuesday, 4 February 2025 at 11.00 - 12.00am CET (corrected from 10.00 - 11.00am CET in an earlier version of this invitation)

In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.

The webcast of the conference call will be available during and after the event. 

Coloplast will be represented by:

Kristian Villumsen - President & CEO

Anders Lonning-Skovgaard - Executive Vice President, CFO

Aleksandra Dimovska - Vice President, Investor Relations

Simone Dyrby Helvind - Senior Manager, Investor Relations 

 

Webcast

For participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below:



Dial-in details

To actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details.

 

 

 

For more information, please contact:

Aleksandra Dimovska - Vice President, Investor Relations

Tel.: / direct: . E-mail: 

Simone Dyrby Helvind - Senior Manager, Investor Relations

Tel.: / direct: . E-mail: 

Julie Isabella Sommer Müggler - Coordinator & PA, Investor Relations

Tel.: / direct: . E-mail: 



Coloplast will be available on individual phone lines after the conference call for further questions.

Attachment



EN
22/01/2025

Underlying

COLO BColoplast A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
COLO B Coloplast A/S C...

Coloplast (Hold, TP: DKK770.00) - Expecting another weak quarter

We expect another soft quarter (7.8% organic revenue growth YOY and a 27.5% EBIT margin), before then improving. We look for unchanged 2024/25 guidance of 8–9% organic sales growth and a c28% EBIT margin before special items. We have cut our 2024/25–2026/27e EPS by 2.8% on average and believe returning to a 30%+ EBIT margin hinges on external factors. We reiterate our HOLD, but have cut our target price to DKK770 (850).

COLO B COLOPLAST A/S CLASS B
04/15/25 April 15, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference...

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST Tuesday, 6 May 2025 at 11.00 - 12.00am CESTIn connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the e...

April 15, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
COLO B Coloplast A/S C...

Coloplast (Hold, TP: DKK850.00) - 2024/25 likely back-end loaded

The Q1 headline results were broadly in line with our forecasts and consensus. We view 2024/25 as back-end loaded and expect a pick-up in organic growth and margins over the coming quarters. The company maintained its 2024/25 guidance for 8–9% organic sales growth and a c28% EBIT margin before special items. We reiterate our HOLD and DKK850 target price.

COLO B COLOPLAST A/S CLASS B
02/04/25 February 4, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
COLO B COLOPLAST A/S CLASS B
02/04/25 February 4, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Allocation of Share Options Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:   Details of the person discharging managerial responsibi...

February 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch